REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

Regenxbio (RGNX) Tops Q2 EPS by 57c, Revenues Miss

August 7, 2019 5:52 PM EDT

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($0.04), $0.57 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $7.88 million versus the consensus estimate of $16.98 million.

"We are encouraged by the continued positive interim data from the Phase I/IIa RGX-314 trial and the potential of NAV gene therapy as a one-time treatment for wet AMD, and look forward to sharing six-month results from all five cohorts in... More